期刊
VACCINE
卷 33, 期 21, 页码 2511-2516出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2014.12.036
关键词
Autism Spectrum Disorder; Risk factor; Measles-Mumps-Rubella vaccine; Thimerosal; Case-control study; Environmental factors
资金
- Ministry of Health, Labor and Welfare of Japan [H22-Psychiatry-General-016]
- Ministry of Education, Culture, Sports, Science and Technology of Japan
Objective: This case-control study investigated the relationship between the risk of Autism Spectrum Disorder (ASD) onset, and early exposure to the combined Measles-Mumps-Rubella (MMR) vaccine and thimerosal consumption measured from vaccinations in the highly genetically homogenous Japanese population. Methods: Vaccination histories at 1, 3, 6, 12, 18, 24, and 36 months from birth were investigated in ASD cases (189 samples), and controls (224 samples) matching age and sex in each case. Crude odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to determine relationship between MMR vaccination and ASD. The differences in mean values of the thimerosal dosage between cases and controls were analyzed using an unpaired t-test. MMR vaccination and thimerosal dosage were also investigated using a conditional multiple-regression model. Results: There were no significant differences in MMR vaccination and thimerosal dosage between cases and controls at any age. Furthermore, the ORs (95% CIs) of MMR vaccination and thimerosal dosage associated with ASD in the conditional multiple regression model were, respectively, 0.875(0.345-2.222) and 1.205(0.862-1.683) at age 18 months, 0.724(0.421-1.243) and 1.343(0.997-1.808) at 24 months, and 1.040(0.648-1.668) and 0.844(0.632-1.128) at 36 months. Thus, there were no significant differences. Conclusions: No convincing evidence was found in this study that MMR vaccination and increasing thimerosal dose were associated with an increased risk of ASD onset. (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据